Entero Healthcare

CSell / Avoid

ENTERO · NSE · Small Cap · Pharmacy Retail

Pharmacy RetailLogistics — 3PL

Fetching live…

₹1,280

1D -0.5%1M -2.5%1Y -22%

Fundamental (RQ-100)

Technical (TQ-100)

Valuation

Market cap

₹5.8K Cr

Live decision ratingCSell / Avoid

Fundamental score breakdown

46/100

Growth Quality

18.8 / 20

Rev 1Y 22.0%, 3Y CAGR 28.0%, 5Y CAGR 25.0%

Margin & Profitability

1.5 / 15

EBITDA 4.0%, PAT 1.0%

Return on Capital

4.4 / 20

ROCE 6.0%, ROE 3.0%

Cash Flow Quality

4.0 / 15

OCF/EBITDA 0.50

Leverage

6.0 / 10

ND/EBITDA 1.00

Reinvestment

3.0 / 8

Capex/Sales 1.0%

Accounting

4.0 / 7

Governance

4.0 / 5

Technical score breakdown

36/100

Trend Structure

8.0 / 20

↓ 200 · ↓ 50 · ↓ 20

Momentum

3.0 / 15

1Y -22.0%, 1M -2.5%

Volume Dynamics

8.0 / 15

Vol30 —%

Relative Strength

2.0 / 15

1Y -22.0%

MA Cluster

5.0 / 10

Extension

5.0 / 10

—% from 50DMA

Volatility

4.0 / 8

Price Action

1.0 / 7

-100.0% from 52W H

Business

What this company actually does

Pharma distribution platform.

Stores

—

Dark stores

—

Cities

—

Listed status

Listed

Format exposure

How direct is this play?

Primary formatPharmacy Retail

Exposure typeMeaningful

Revenue visibilityLow

Operating leverage stageInvestment

Policy beneficiaryNone

Data confidenceMedium

Financial snapshot

Live · green dot = live, falls back to curated

Revenue

₹4.5K Cr

Rev 1Y growth

22%

Rev 3Y CAGR

28%

EBITDA margin

4.0%

PAT margin

1.0%

ROE

ROCE

OCF/EBITDA

0.50

Net Debt/EBITDA

1.0

Financial statements

Multi-year P&L, balance sheet, cash flow — scraped live from Screener.in

Fetching from Screener.in…

Loading…

Valuation

Live multiples + retail-specific (curated)

P/E

Forward P/E

EV/EBITDA

EV/Sales

1.2

P/B

4.0

FCF Yield

2.1%

Mid-range valuation. Watch incremental ROCE.

Investment thesis

AI-generated · always cite sources before acting

Bull

Compounding revenue at 28% CAGR. Long-runway TAM with structural tailwinds.

Base

Earnings growth of ~31% over the next 3 years assuming margins hold. Multiple compression risk if growth slows; multiple expansion possible if Pharmacy Retail GMV outperforms.

Bear

Capital efficiency below cost of capital. Format-level risk: regulation, gig-cess, or competitive pressure compress contribution margin.

Variant perception

Consensus views Entero Healthcare as a challenged player. Our differentiated take: the current multiple already prices in mid-cycle outcomes.

Key monitorables

Quarterly EBITDA margin trajectory
Revenue growth vs management guidance
Capex vs store/dark-store adds
Promoter holding and ESOP dilution

Peers

Same primary format · sorted by market cap